Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 5% in early trading, currently up 3.95% at HKD 11.85, with a trading volume of HKD 36.6973 million, following the announcement of a voluntary lock-up commitment by the controlling shareholder before key clinical data releases [1] Group 1: Clinical Trials and Data Releases - The controlling shareholder has committed not to sell any shares before the release of three key clinical data points: 1. Topline data from the U.S. Phase I clinical study of ASC47 combined with semaglutide in obese subjects, expected by the end of September 2025 2. Topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects, expected by December 2025 3. Topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by December 2025 [1][1][1] Group 2: Drug Development and Potential - The company recently announced that the small molecule GLP-1R agonist ASC30 has shown an apparent half-life of 75 days in obese subjects, indicating the potential for developing a long-term weight management solution with quarterly dosing [1][1] - ASC30 is developed using the company's ultra-long-acting drug development platform (ULAP), and the company has multiple pipelines relying on this platform to develop long-acting formulations, which may meet various clinical needs [1][1]
歌礼制药-B早盘涨超5% 控股股东作出自愿禁售承诺 ASC30有望推出季度制剂